{"doi":"10.1053/j.ajkd.2024.02.006","title":"Glycated Albumin and Adverse Clinical Outcomes in Patients With CKD: A Prospective Cohort Study","abstract":null,"journal":"American Journal of Kidney Diseases","year":2024,"id":610938,"datarank":0.4566783656585135,"base_score":3.044522437723423,"endowment":3.044522437723423,"self_citation_contribution":0.4566783656585135,"citation_network_contribution":0.0,"self_endowment_contribution":0.4566783656585135,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":20,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":253969,"name":"Anders H. Berg","orcid":"0000-0002-5736-0686","position":1,"is_corresponding":false},{"id":546739,"name":"Hui Zheng","orcid":"0000-0001-9735-5657","position":2,"is_corresponding":false},{"id":268754,"name":"Eugene P. Rhee","orcid":"0000-0002-4804-7583","position":3,"is_corresponding":false},{"id":279520,"name":"Andrew S. Allegretti","orcid":"0000-0001-9416-6623","position":4,"is_corresponding":false},{"id":434244,"name":"Sagar U. Nigwekar","orcid":"0000-0002-6750-0072","position":5,"is_corresponding":false},{"id":293224,"name":"S. Ananth Karumanchi","orcid":"0000-0002-2281-6831","position":6,"is_corresponding":false},{"id":264926,"name":"James P. Lash","orcid":null,"position":7,"is_corresponding":false},{"id":279522,"name":"Sahir Kalim","orcid":"0000-0002-1746-5790","position":8,"is_corresponding":false},{"id":905052,"name":"Mengyao Tang","orcid":"0000-0003-3754-9518","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Glycated Albumin and Adverse Clinical Outcomes in Patients With CKD: A Prospective Cohort Study","abstract":"Rationale & Objective HbA 1c is widely used to estimate glycemia, yet it is less reliable in patients with chronic kidney disease (CKD). There is growing interest in the complementary use of glycated albumin (GA) to improve glycemic monitoring and risk stratification. However, whether GA associates with clinical outcomes in a non-dialysis dependent CKD population remains unknown. Study Design Prospective cohort study. Setting & Participants: 3110 participants with CKD from the Chronic Renal Insufficiency Cohort study. Exposure Baseline GA levels. Outcomes Incident end-stage kidney disease (ESKD), cardiovascular disease (CVD) events, and all-cause mortality. Analytical Approach Cox proportional hazards regression. Results Participant characteristics included mean age 59.0 (SD 10.8) years; 1357 (43.6%) female; 1550 (49.8%) with diabetes. The median GA was 18.7 (interquartile range, 15.8-23.3)%. During an average 7.9-year follow-up, there were 980 ESKD events, 968 CVD events, and 1084 deaths. Higher GA levels were associated with greater risks of all outcomes, regardless of diabetes status: hazard ratios for ESKD, CVD, and death among participants with the highest quartile compared with quartile 2 (reference) were 1.42 (95%CI, 1.19-1.69), 1.67 (CI, 1.39-2.01), and 1.63 (CI, 1.37-1.94), respectively. The associations with CVD and death appeared J-shaped, with increased risk also seen at the lowest GA levels. Among patients with coexisting CKD and diabetes, the associations of GA with outcomes remained significant even after adjusting for HbA 1c. For each outcome, we observed a significant increase in the fraction of new prognostic information when both GA and HbA 1c were added to models. Limitations Lack of longitudinal GA measurements; HbA 1c measurements were largely unavailable in participants without diabetes. Conclusions Among patients with CKD, GA levels were independently associated with risks of ESKD, CVD, and mortality, regardless of diabetes status. GA added prognostic value to HbA 1c among patients with coexisting CKD and diabetes.","is_dataset_classified":null,"base_score":3.044522437723423,"endowment":3.044522437723423,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"38518919","pmcid":"PMC11344690","openalex_id":"https://openalex.org/W4392978257","authors":[],"funders":[{"funder_name":"American Heart Association Inc","grant_id":"AHA23POST1010825","title":null},{"funder_name":"National Heart, Lung, and Blood Institute","grant_id":"K24DK092290","title":null},{"funder_name":"National Heart, Lung, and Blood Institute","grant_id":"R01DK072231-91","title":null},{"funder_name":"National Heart, Lung, and Blood Institute","grant_id":"R01HL133399","title":null},{"funder_name":"National Heart, Lung, and Blood Institute","grant_id":"U01DK060980","title":null},{"funder_name":"National Heart, Lung, and Blood Institute","grant_id":"K23DK128567","title":null},{"funder_name":"NIDDK NIH HHS","grant_id":"R01 DK072231","title":null},{"funder_name":"NIDDK NIH HHS","grant_id":"R01 DK124453","title":null},{"funder_name":"American Heart Association-American Stroke Association","grant_id":"23POST1010825","title":null}],"total_grants":9,"fwci":5.2773,"citation_percentile":0.96521864,"influential_citations":0,"citation_trend":[{"year":2024,"count":5},{"year":2025,"count":8},{"year":2026,"count":7}],"oa_status":"hybrid","license":"cc-by-nc-nd","oa_locations":[{"url":"http://www.ajkd.org/article/S0272638624006838/pdf","host_type":"journal"},{"url":"http://www.ajkd.org/article/S0272638624006838/pdf","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0272638624006838?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0272638624006838?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1053/j.ajkd.2024.02.006","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/38518919","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/11344690","host_type":"repository"},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11344690/","host_type":"repository"},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11344690/pdf/nihms-1980164.pdf","host_type":"repository"}],"fields_of_study":["Diabetes Treatment and Management","Chronic Kidney Disease and Diabetes","Diabetes Management and Research","Humans","Female","Male","Middle Aged","Glycation End Products, Advanced","Glycated Serum Albumin","Prospective Studies","Renal Insufficiency, Chronic","Serum Albumin","Aged","Cardiovascular Diseases","Kidney Failure, Chronic","Cohort Studies","Glycated Hemoglobin"],"mesh_terms":["Glycated Serum Albumin","Aged","Cardiovascular Diseases","Female","Glycated Hemoglobin","Humans","Kidney Failure, Chronic","Male","Middle Aged","Prospective Studies","Serum Albumin","Cohort Studies","Glycation End Products, Advanced","Renal Insufficiency, Chronic"],"keywords":["Medicine","Prospective cohort study","Internal medicine","Adverse effect","Glycated haemoglobin","Cohort study","Albumin","Cohort","Intensive care medicine","Diabetes mellitus","Endocrinology","Type 2 diabetes","Chronic Kidney Disease","Glycated Albumin","Clinical Epidemiology"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Zero hunger"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-01T13:14:52.663900Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}